Capnia, Inc. (CAPN) Starts Presentation at Marcum MicroCap Conference

Capnia (NASDAQ: CAPN) develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. The company’s lead product, CoSense®, is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the EU. Capnia’s proprietary therapeutic technology uses nasal, non-inhaled CO2 and is being evaluated to treat the symptoms of allergies, as well as the trigeminally mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine. For more information, visit the company’s website at www.capnia.com